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A 37-year male presented with cough and dyspnoea for 9 months that had worsened over the past 7 days 
and was complicated by haemoptysis. Haemoptysis was moderate in amount with 3–4 episodes per day consi-
sting of fresh red blood and was not associated with bleeding from any other site. There was no history of fever 
or weight loss. Dyspnoea was persistent and progressive to dyspnoea at rest on presentation. Two years ago, 
the patient had undergone 6 months of anti-tubercular therapy for sputum positive pulmonary tuberculosis. 
On examination, the patient was conscious and oriented. His blood pressure was 110/70 mm Hg, pulse 
was 120/minute and respiratory rate was 34/min. Pallor was present but without any icterus, pedal oedema or 
lymphadenopathy. Respiratory system examination revealed vesicular breath sounds with bilateral crackles. 
Investigations revealed Haemoglobin 9 gram% with normal organ function tests and hypoxemic respiratory 
failure. Chest X-ray and a CT examination of the chest are provided below (Figure 1 A–E). 
Flexible bronchoscopy was essentially normal. Sequential bronchoalveolar lavage (BAL) fluid instillation 
became progressively bloodier upon aspiration and contained hemosiderin-laden macrophages confirming 
diffuse alveolar haemorrhage (DAH). BAL was negative for acid-fast bacilli (AFB), pneumocystis pneumonia 
(PCP), fungal mount, malignant cytology, and pyogenic/mycobacterial culture.
Figure 1. A. Chest	X-ray	showing	bilateral	cavitary	lesions	with	right	lower	zone	opacities;	B–E.	CECT	chest	suggestive	of	bilateral	cavities	
with	a	fungal	ball	in	the	left	upper	lobe	cavity.	Also,	bilateral	dense	alveolar	opacities	are	present	and	are	more	prevalent	in	the	right	lower	
lobe;	F. Chest	X-ray	showing	resolution
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Serum precipitins and IgG against aspergillus were positive. Further probing revealed a history of inter-
mittent episodes of epistaxis for 4 years which had spontaneously resolved. Further laboratory investigations 
revealed a positive c-ANCA by ELISA and anti-PR3 antibodies. Urine investigations were suggestive of 10–12 
RBC with 24-hour protein of 400 mg%. 
The American College of Rheumatology (ACR) 1990 classification criteria [1] for GPA was fulfilled by three 
out of four criteria (bloody nasal discharge, lung cavity, and ≥ 5 RBC in urine analysis). The 2017 proposed 
ACR/EULAR criteria require 5 points for a diagnosis; our patient satisfied 10 points (5 points for ANCA, 2 for 
lung cavity and 3 for epistaxis). This criterion is, however, suggested for clinical trials and the ACR suggests 
not to use it for diagnosis. Diffuse alveolar haemorrhage (DAH) presents with haemoptysis, anaemia or falling 
haematocrit, diffuse lung infiltration, and acute respiratory failure [2]. Our patient had all these features of 
DAH. It is difficult to diagnose DAH early because of its abrupt onset and rapid progression as well as because 
of its non-specific clinical symptoms and radiographic findings. The alveolar infiltrates can be unilateral, and 
a drop in hematocrit can be difficult to document [3]. 
The patient needed steroids and immunosuppressants, but also had CPA. The diagnosis of CPA requires 
consistent appearance in thoracic imaging (preferably by CT), direct evidence of Aspergillus infection or an 
immunological response to Aspergillus spp, and exclusion of some alternative diagnoses. In addition, at least 
3 months of duration of disease are needed, even if inferred from or based on symptoms, or visualized on 
progressive radiological abnormalities [4]. Our patient had a lung cavity with positive serology to Aspergillus. 
Thus, the patient had a diagnosis of old treated pulmonary tuberculosis with GPA presenting as DAH with CPA. 
A cut-off of 10 mg prednisolone daily (or its equivalent) is arbitrarily considered to cause immunosuppression 
during clinical management. Intermittent higher levels of immunosuppression may accelerate progression of 
CPA if not controlled with antifungal therapy [4].
A case series found that seven ANCA-associated vasculitis patients developed invasive pulmonary 
aspergillosis when treated with steroids and immunosuppressants [5]. Therefore, they recommend that pro-
phylactic antifungals should be given to high risk patients, especially those who are on immunosuppression. 
The patient was given parenteral cyclophosphamide 750 mg for 1 day and methylprednisolone 1 g for 3 days 
under cover of intravenous voriconazole 200 mg every 12 hours. 
Haemoptysis of the patient resolved in 2 to 3 days and room air saturation became 99%. The patient was 
discharged on oral prednisolone 1 mg/kg and oral voriconazole 200 mg twice daily and asked to follow up for 
subsequent pulses with cyclophosphamide. Chest X-ray at discharge (Figure 1F) showed resolution.
To conclude, cavitating lung diseases have varied etiologies and more than one apparent cause may be 
present simultaneously. Early diagnosis and treatment of diffuse alveolar hemorrhage can reduce mortality. 
Prophylactic antifungal treatment may be warranted in patients with an Aspergillosis infection who are put 
on immunosuppressant therapy.
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